The Latest

  • story image
    Image attribution tooltip
    Seth Babin/BioPharma Dive
    Deep Dive

    Heart attacks struck Sek Kathiresan's family. He's devoted his life to stopping them.

    After several family members had early heart attacks, Kathiresan vowed to understand why they happen. His research journey has changed medical practice and led to a new biotech startup, Verve Therapeutics, that seeks to prevent them.

  • Image attribution tooltip
    Courtesy of Eli Lilly

    Lilly drug becomes first COVID antibody cleared for use in young children

    The emergency clearance from the FDA allows for treatment of mild and moderate disease as well as prevention in those exposed and at high risk.

  • Image attribution tooltip
    "SEC" by SEC is licensed under CC BY 2.0

    Former Immunomedics executive charged with insider trading around trial data

    Usama Malik, chief financial officer of Immunomedics from 2017 to late 2020, is charged with tipping his partner and several relatives of positive study results for the biotech's breast cancer drug.

  • Sobi buyout breaks down

    Three months after proposing a roughly $8 billion acquisition of Sobi, the investment firms Advent International and GIC have withdrawn their offer.

  • Image attribution tooltip
    Novartis

    Novartis pays $150M for access to UCB's Parkinson's drug

    UCB's experimental pill is one of the most advanced projects that's aimed at blocking accumulation of an abnormal protein in patients' brains.

  • story image
    Image attribution tooltip
    Adeline Kon/BioPharma Dive
    Deep Dive

    Biotech M&A, while far from recent heights, is picking back up. Here are the latest deals.

    Recordati, a private equity-owned Italian pharmaceutical firm, is buying the U.K.'s EUSA Pharma for an enterprise value of nearly $850 million. 

    Updated Dec. 2, 2021
  • Image attribution tooltip
    National Institute of Allergy and Infectious Diseases. (2020). "Novel Coronavirus SARS-CoV-2" [Micrograph]. Retrieved from Flickr.

    Early tests suggest Vir, GSK antibody could hold up versus omicron

    But more complete testing, which would give a better sense of the drug's potency against the variant, is still ongoing as researchers work to assess omicron's threat.

  • Image attribution tooltip
    Getty / Edited by BioPharma Dive

    A startup led by Novartis veteran raises $80M to develop gene therapies for the brain

    AviadoBio, which was built around research from the lab of Christopher Shaw at King's College London, is backed by venture firms NEA and Monograph Capital.

  • Image attribution tooltip
    atiatiati via Getty Images

    Facing challenges, Deciphera cuts workforce by a third

    The Massachusetts biotech is eliminating 140 positions as it looks to cut costs following disappointing study results for its sole commercial product.

  • Image attribution tooltip
    National Institute of Allergy and Infectious Diseases. (2020). "Novel Coronavirus SARS-CoV-2" [Image]. Retrieved from Flickr.

    Regeneron warns its antibody drug may be less potent versus omicron

    While Regeneron is still testing its treatment against the variant, the biotech is readying contingency plans, including second-generation versions of its drug.

  • story image
    Image attribution tooltip
    Brian Tucker/BioPharma Dive
    Deep Dive

    Coronavirus vaccines are rolling out quickly. Here's where the pipeline stands.

    Fuller data in hand, Pfizer and BioNTech plan to soon seek full U.S. approval for their vaccine in 12- to 15-year-olds. 

    Updated Nov. 24, 2021
  • Image attribution tooltip
    National Institute of Allergy and Infectious Diseases. (2020). "Novel Coronavirus SARS-CoV-2" [Micrograph]. Retrieved from Flickr.

    Vaccine makers move quickly to confront omicron threat

    Several companies, including Pfizer and Moderna, are already at work adapting their coronavirus shots to the newly identified variant, which experts worry could more readily evade vaccine protection.

  • Image attribution tooltip
    SciePro via Getty Images

    Blueprint, taking aim at larger drugmakers, becomes a biotech buyer

    A $250 million acquisition of startup Lengo Therapeutics has given Blueprint a lung cancer drug that could compete with medicines from Takeda and J&J.

  • Image attribution tooltip
    Courtesy of Merck & Co.

    New Merck study results raise questions about its COVID pill

    Final trial data for molnupiravir were less convincing than what Merck previously reported and could alter how the FDA views the drug, which will be evaluated at a meeting Tuesday.

  • Image attribution tooltip
    cgtoolbox via Getty Images

    With safety a concern, Merck, Gilead pause study of HIV drugs

    Out of an "abundance of caution," the companies halted enrollment in a trial evaluating the combination of Merck's islatravir and Gilead's lenacapavir.

  • story image
    Image attribution tooltip
    Adeline Kon/BioPharma Dive
    Deep Dive

    Record numbers of biotechs are going public. Here's how they're performing.

    Vigil Neuroscience and Bionomics, which just outlined their IPO plans, could become the eighth and ninth neurological drug developers to go public in 2021, a total that would eclipse each of the previous three years. 

    Updated Nov. 23, 2021
  • Image attribution tooltip
    Dr_microbe via Getty Images

    Takeda wins US approval for new CMV treatment

    The antiviral drug, which has been a top research focus of Takeda for years, is the first to be cleared by the FDA for post-transplant CMV infections that are resistant to other treatments.

  • GSK dives into NASH, RNA interference with Arrowhead deal

    GSK has secured rights to a genetic medicine in early-stage human testing for NASH, a disease thought to affect millions of people that has proven to be a tough target for drugmakers. 

  • Image attribution tooltip
    Courtesy of AstraZeneca

    AstraZeneca, after years of delays, opens UK hub meant to recharge drug research

    Formally unveiled five years after originally planned, the $1 billion headquarters will become the British drugmaker's second-largest R&D center by headcount.

  • Image attribution tooltip
    Antonio Masiello via Getty Images

    Pfizer, BioNTech to seek full approval as COVID-19 vaccine efficacy holds up in young teens

    Four months after vaccination, no 12- to 15-year-olds in the companies' clinical trial developed COVID-19, compared to 30 who received a placebo.

  • story image
    Image attribution tooltip
    Adeline Kon / BioPharma Dive/BioPharma Dive
    Deep Dive

    A three-decade monopoly: how Amgen built a patent thicket around its top-selling drug

    Through high-stakes litigation, aggressive patenting practices and a bit of luck, Amgen will likely stretch Enbrel's monopoly until 2029, more than 30 years after it was approved.

  • Image attribution tooltip
    Novo Nordisk

    Novo to acquire Dicerna for more than $3B amid RNA drug resurgence

    The acquisition would give Novo Nordisk ownership of one of the oldest and largest developers of RNA interference drugs, along with a web of potential royalty streams. 

    Updated Nov. 18, 2021
  • Image attribution tooltip
    Getty Images

    Neurocrine stocks up on a biotech's psychiatric drugs

    A new deal with Sosei Heptares hands Neurocrine a "broad portfolio" of drugs for schizophrenia, dementia and other neuropsychiatric disorders.

  • Image attribution tooltip
    libre de droit via Getty Images

    Bluebird, after delays, gets speedy FDA review for beta thalassemia gene therapy

    The regulator will decide whether to approve Bluebird's treatment by next May, but its evaluation is beginning more than a year later than the biotech hoped.

  • Image attribution tooltip
    Sarah Silbiger via Getty Images

    FDA, aiming to curb another COVID-19 surge, clears Pfizer, Moderna boosters for all adults

    Soon after the FDA's authorization, a panel of CDC advisers followed with similar recommendations for third doses in adults over 18 years old. 

    Updated Nov. 20, 2021